U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT06914934) titled 'Study of High-Dose Resveratrol in Patients With Stable Ischemic Heart Disease' on April 04.
Brief Summary: This 6-month, randomized, double-blind, placebo-controlled pilot study investigates whether high-dose resveratrol (500 mg/day), when added to standard therapy, can improve endothelial function and reduce inflammation in patients with stable ischemic heart disease. While preclinical data and small trials have shown promising effects on vascular health and inflammation, larger studies have lacked consistent results. This study aims to provide more robust clinical evidence by assessing flow-mediated dilation (FMD) and high-sensiti...